Amgen and Entera Bio have announced that they have entered into a research collaboration and license agreement to develop orally administered formulations of biologic drugs.
Amgen and Entera Bio have announced that they have entered into a research collaboration and license agreement to develop orally administered formulations of biologic drugs.
Entera will use its proprietary platform to develop the formulations, first for 1 preclinical large-molecule product that Amgen has selected. Amgen also retains an option for up to 2 additional programs to be included in the collaboration.
Entera, an Israel-based clinical-stage biotech company, says that its technology consists of 2 components: a small molecule that enhances absorption of large-molecule therapeutics, and a component that protects the large molecule from digestion in the gastrointestinal tract. This system, it says, increase oral bioavailability and decreases variability associated with oral administration of large molecules.
“We are excited to leverage our proprietary oral drug delivery platform in collaboration with Amgen, a leader in the development of large molecule and biologic treatments in inflammatory disease and numerous other disorders,” said Phillip Schwartz, PhD, CEO of Entera, in a statement. “This collaboration is an important validation of our platform technology.”
Under the terms of the agreement, Entera will receive an access fee from Amgen and will undertake preclinical development of the proposed product at Amgen’s expense. As it achieves various clinical and commercial milestones, Entera will be eligible to receive up to $270 million from Amgen in aggregate payments, plus tiered royalties.
Entera and Amgen are not the first to venture into the world of oral biologics; a fellow Israel-based company, Protalix BioTherapeutics, Inc, announced in March of this year that its OPRX-106, an orally administered biologic, had met its key efficacy end points in a phase 2 clinical trial. Protalix’s proposed drug is a plant cell—expressed recombinant human tumor necrosis factor (TNF) receptor II fused to an IgG1 Fc domain that is intended to treat inflammatory bowel disease.
Protalix says that the plant cells in its drug act as a delivery vehicle and have a unique attribute of a cellulose cell wall that allows them to resist the degradation that is inherent to proteins produced via mammalian expression as they pass through the digestive tract.
At least 1 other developer has attempted to produce an oral TNF inhibitor; in 2016, Avaxia Biologics reported positive results of a first-in-human trial of its AVX-470, a polyclonal bovine-derived anti-TNF drug, in patients with ulcerative colitis, saying that the agent was safe and well tolerated in the trial. However, Circle33 LLC, which later acquired the patent on the product, had not reported further developments.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.